Cargando…
Dendritic cell vaccination plus low-dose doxorubicin for the treatment of spontaneous canine hemangiosarcoma
Angiosarcoma is a deadly neoplasm of the vascular endothelium. Metastatic disease is often present at diagnosis, and 5-year survival is only 10–35%. Although there exist no immunocompetent mouse models of angiosarcoma with which to study immune-based approaches to therapy, angiosarcoma is a major ki...
Autores principales: | Konduri, V., Halpert, M. M., Baig, Y. C., Coronado, R., Rodgers, J. R., Levitt, J. M., Cerroni, B., Piscoya, S., Wilson, N., DiBernardi, L., Omarbekov, Z., Seelhoff, L., Ravi, V., Douglass, L., Decker, W. K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760631/ https://www.ncbi.nlm.nih.gov/pubmed/30670791 http://dx.doi.org/10.1038/s41417-019-0080-3 |
Ejemplares similares
-
Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma
por: Gardner, Heather L., et al.
Publicado: (2015) -
Pilot safety evaluation of doxorubicin chemotherapy combined with non-specific immunotherapy (Immunocidin®) for canine splenic hemangiosarcoma
por: Musser, Margaret L., et al.
Publicado: (2022) -
Actionable mutations in canine hemangiosarcoma
por: Wang, Guannan, et al.
Publicado: (2017) -
Constitutive expression and roles of interleukin-8 in canine hemangiosarcoma
por: Kim, Jong-Hyuk, et al.
Publicado: (2013) -
Canine hemangiosarcoma in a female Jindo dog
por: Mun, Ahlyum, et al.
Publicado: (2011)